TARGET-DERM+ is an observational research study to conduct a comprehensive review of outcomes for patients with dermatologic disease (DD) and providers who treat these patients. The study includes patients managed for DD of any etiology in usual clinical practice in the United States and addresses important clinical questions regarding the management of DD by collecting and analyzing data from patients at academic medical centers and community medical practices and/or data from providers who treat them.
Eligibility
Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Adult or pediatric participants managed for DD invited to participate OR a provider who treats patients with these conditions. Informed consent is required for all Engaged Cohort participants.
* Adult or pediatric participants at the time of enrollment with a diagnosis of DD by ICD code or other relevant healthcare code as part of the EHR interface.
Exclusion Criteria:
* Participant withdrew consent; Failure to complete activities as required per the cohort clarification letter.
Primary outcome measure(s)
To assess safety and effectiveness of DD treatments and treatments for complications of any dermatologic disease — 15 years The study will evaluate the characteristics of patients receiving various treatments, effectiveness of treatment, and medical events that develop while receiving treatment for DD
To characterize the natural history of disease in patients with dermatologic disease from various etiologies — 15 years A detailed analysis of available demographics (age, race, sex, country of birth, insurance status), medications, co-morbidities, and medical history from sites across the US will inform the profile for this patient population.
To establish learning health networks focused on quality of care for patients — 15 years Identify deficiencies and best practices in care of patients with DD.
• Evaluate outcomes from targeted learning content in the management of patients with DD.
Trial sites (1)
Facility
City
Region
Status
Greenwich Village Dermatology
New York
New York
More Target PharmaSolutions, Inc. trials in the USA
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.